Minimal residual disease – ready for prime time in follicular lymphoma?

The possible role of minimal residual disease (MRD) in the management of patients with follicular lymphoma (FL) has been a recurrent topic in this field for at least two decades. In this issue of the journal, Pulsoni I et al i ([9]) report a study using MRD, determined in bone marrow (BM) and/or peripheral blood (PB), in patients with early stage FL treated with involved-field radiotherapy (IF-RT). More recently, interest has been raised regarding the application of more modern techniques to detect MRD, including next generation sequencing (NGS), in the search for biomarkers that may help in adapting therapy to the disease risk. [Extracted from the article]